The higher initial dose and accelerated titration regimen of ropeginterferon as a treatment option for certain patients with polycythaemia vera.
作者信息
Qin Albert, Zhang Lei, Jin Jie
机构信息
PharmaEssentia Corporation, Taipei, Taiwan.
State Key Laboratory of Experimental Haematology, National Clinical Research Center for Blood Diseases, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
出版信息
Br J Haematol. 2025 Mar;206(3):986-987. doi: 10.1111/bjh.19998. Epub 2025 Jan 12.
Abstract
摘要
相似文献
1
The higher initial dose and accelerated titration regimen of ropeginterferon as a treatment option for certain patients with polycythaemia vera.聚乙二醇干扰素的较高初始剂量和加速滴定方案作为真性红细胞增多症某些患者的一种治疗选择。
Br J Haematol. 2025 Mar;206(3):986-987. doi: 10.1111/bjh.19998. Epub 2025 Jan 12.
2
Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.聚乙二醇干扰素α-2b治疗真性红细胞增多症患者的暴露-疗效和暴露-安全性分析。
Br J Clin Pharmacol. 2024 Jun;90(6):1493-1502. doi: 10.1111/bcp.16043. Epub 2024 Mar 19.
3
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.罗哌戈汀干扰素 α-2b 与放血疗法治疗低危真性红细胞增多症患者（Low-PV 研究）：一项多中心、随机 2 期临床试验。
Lancet Haematol. 2021 Mar;8(3):e175-e184. doi: 10.1016/S2352-3026(20)30373-2. Epub 2021 Jan 18.
4
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.聚乙二醇干扰素α-2b对比真性红细胞增多症标准疗法（PROUD-PV和CONTINUATION-PV）：一项随机、非劣效性3期试验及其扩展研究。
Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31.
5
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.聚乙二醇干扰素α-2b在中国和日本真性红细胞增多症患者中的群体药代动力学-药效学及暴露-反应关系
Pharmacol Res Perspect. 2025 Jun;13(3):e70109. doi: 10.1002/prp2.70109.
6
7
A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.罗特西普干扰素 α-2b 治疗真性红细胞增多症的药代动力学评价。
Expert Opin Drug Metab Toxicol. 2021 Jan;17(1):3-7. doi: 10.1080/17425255.2021.1839050. Epub 2020 Oct 29.
8
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.聚乙二醇干扰素α-2b的一种新给药方案高效且耐受性良好：一项针对中国真性红细胞增多症患者的2期研究结果
Exp Hematol Oncol. 2023 Jun 21;12(1):55. doi: 10.1186/s40164-023-00415-0.
9
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).在接受聚乙二醇化干扰素α-2a（派罗欣）治疗后，使用罗培戈干扰素α-2b（贝丝瑞美）治疗真性红细胞增多症和原发性血小板增多症的真实世界经验。
Leuk Res Rep. 2022 Dec 16;19:100360. doi: 10.1016/j.lrr.2022.100360. eCollection 2023.
10
A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.一项评估罗特西普干扰素α-2b 在中国真性红细胞增多症患者中的疗效和安全性的 II 期临床试验。
Future Oncol. 2023 Apr;19(11):753-761. doi: 10.2217/fon-2022-1141. Epub 2023 May 2.
引用本文的文献
1
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.2025年亚洲骨髓增殖性肿瘤大会亮点：骨髓增殖性肿瘤分子发病机制与治疗策略的进展
Curr Hematol Malig Rep. 2025 Jul 12;20(1):9. doi: 10.1007/s11899-025-00752-3.
2
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.聚乙二醇干扰素α-2b在中国和日本真性红细胞增多症患者中的群体药代动力学-药效学及暴露-反应关系
Pharmacol Res Perspect. 2025 Jun;13(3):e70109. doi: 10.1002/prp2.70109.
本文引用的文献
1
The dosage of ropeginterferon in polycythaemia vera: Balancing efficacy, safety and pharmacoeconomics across risk categories.真性红细胞增多症中罗普司亭的剂量：平衡不同风险类别下的疗效、安全性和药物经济学
Br J Haematol. 2025 Mar;206(3):984-985. doi: 10.1111/bjh.19996. Epub 2025 Jan 12.
2
Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b.在真性红细胞增多症患者接受聚乙二醇干扰素α-2b治疗过程中，分子学缓解与完全血液学缓解未同时出现。
Br J Haematol. 2024 Dec;205(6):2510-2514. doi: 10.1111/bjh.19846. Epub 2024 Oct 27.
3
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b.聚乙二醇干扰素α-2b治疗真性红细胞增多症的药代动力学、疗效和安全性的种族敏感性分析。
Front Pharmacol. 2024 Sep 24;15:1455979. doi: 10.3389/fphar.2024.1455979. eCollection 2024.
4
A plain language summary about a cell cycle-based, new surveillance mechanism against cancer.一篇关于基于细胞周期的新型癌症监测机制的通俗易懂的总结。
Future Oncol. 2024 Dec;20(39):3209-3212. doi: 10.1080/14796694.2024.2402649. Epub 2024 Sep 26.
5
Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b.在接受罗特西普干扰素 alfa-2b 治疗的低危原发性血小板增多症日本患者中的疗效和安全性结局。
Int J Hematol. 2024 Aug;120(2):151-156. doi: 10.1007/s12185-024-03804-1. Epub 2024 Jul 1.
6
Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment.聚乙二醇干扰素α-2b治疗真性红细胞增多症的作用机制
Clin Ther. 2024 May;46(5):439-440. doi: 10.1016/j.clinthera.2024.03.005. Epub 2024 May 1.
7
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.用聚乙二醇干扰素α-2b治疗有效管理真性红细胞增多症
J Hematol. 2024 Apr;13(1-2):12-22. doi: 10.14740/jh1245. Epub 2024 Apr 9.
8
Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.聚乙二醇干扰素α-2b治疗真性红细胞增多症患者的暴露-疗效和暴露-安全性分析。
Br J Clin Pharmacol. 2024 Jun;90(6):1493-1502. doi: 10.1111/bcp.16043. Epub 2024 Mar 19.
9
An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1.通过干扰素-β与视网膜母细胞瘤蛋白RB1之间的相互作用进行的抗癌监测。
Front Oncol. 2023 Apr 27;13:1173467. doi: 10.3389/fonc.2023.1173467. eCollection 2023.
10
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.芦可替尼与最佳可用疗法治疗不耐受或对羟基脲耐药的真性红细胞增多症的随机试验。
J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1.
Zotero 插件